Associate Sponsors
  • Quotes

  • NAVs

  • News

  • Messages

  • Opinions

  • Notices

  • Videos

BUDGET CNBC-TV18 Markets Mutual Funds IPO Wealth Portfolio Messages Specials Videos Mail
CNBC-TV18 Matrix SENSEX 14913.05 254.56 NIFTY 4424.25 75.40
 

Feedback

Aurobindo receives 2 more USFDA approvals

Published on Thu, Jan 04, 2007 at 13:48 , Updated at Thu, Jan 04, 2007 at 15:22
Source : Moneycontrol.com

Email    Print      

Aurobindo Pharma Limited is pleased to announce that the company has received two more approvals from the US FDA for Bisoprolol 5 mg, 10 mg & Amoxicillin oral suspension 200mgml, and 400mgml. This is Aurobindo’s 34th & 35th generic approval given by US FDA respectively.

 

Amoxicillin oral suspension is a Beta-lactam antibiotic used often in treating respiratory infections. GSK is the inventor of this antibiotic and is marketed under the brand name Amoxil.

 

Bisoprolol is a beta1-selective (cardioselective) adrenoceptor-blocking agent. It belongs to the group called Beta-blockers. Bisoprolol tablets are employed in managing cardiovascular diseases such as hypertension, coronary heart diseases and arrhythmias etc. Bisoprolol is the original product of MS Duramed Pharms Barr and is known as Zebeta.

 

These two products currently command a market size of USD 100 mio (appx) in USA which enhances Aurobindo’s opportunity in Generics business.

 

Sourced From: Aurobindo Pharma Limited

 

 

More News
View Comments    |    Post Comments
Headlines from Web18
CNBC-TV18
Watch Show
Show Schedule
Transcripts
Videos
Top News
Most Read
just
com